English
Home > Products > Celecoxib intermediate

China Celecoxib intermediate Factory

Our growth depends to the superior products ,great talents and repeatedly strengthened technology forces for Celecoxib intermediate,CAS NO 27918-19-0,27918-19-0,Celecoxib advance intermediate,4-Sulfonamide-phenylhydrazine hydrochloride, Our firm quickly grew in size and reputation because of its absolute dedication to superior quality manufacturing, substantial price of solutions and fantastic customer services.
Celecoxib intermediate, We rely on high-quality materials, perfect design, excellent customer service and the competitive price to win the trust of many customers at home and abroad. 95%products are exported to overseas markets.

Related Products

Hot Products

  • Lenvatinib

    Lenvatinib

    Product Name:Lenvatinib
    Molecular Formula:C21H19ClN4O4
    Molecular Weight;426.85
    CAS Registry Number;417716-92-8
  • BenzenaMine, 2-broMo-5-fluoro-4-nitro-

    BenzenaMine, 2-broMo-5-fluoro-4-nitro-

    Product Name:BenzenaMine, 2-broMo-5-fluoro-4-nitro-
    Molecular Formula:C6H4BrFN2O2
    Molecular Weight:235.01
    CAS Registry Number:952664-69-6
  • 2,5-Difluorophenylacetic acid

    2,5-Difluorophenylacetic acid

    Product Name:2,5-Difluorophenylacetic acid
    Molecular Formula:C8H6F2O2
    Molecular Weight:172.13
    CAS Registry Number:85068-27-5
  • Liranaftate

    Liranaftate

    Product Name:Liranaftate
    Molecular Formula:C18H20N2O2S
    Molecular Weight;328.43
    CAS Registry Number;88678-31-3
  • Trimethyl borate

    Trimethyl borate

    Product Name:Trimethyl borate
    Molecular Formula:C3H9BO3
    Molecular Weight:103.91
    CAS Registry Number:121-43-7
  • (Z)-3-(3-chloropropyl)-7,8-diethyl-1H-benzo[d] azepin-2 (3H)-one

    (Z)-3-(3-chloropropyl)-7,8-diethyl-1H-benzo[d] azepin-2 (3H)-one

    Product Name:(Z)-3-(3-chloropropyl)-7,8-diethyl-1H-benzo[d] azepin-2 (3H)-one
    Molecular Formula:C15H18ClNO3
    Molecular Weight:295.76
    CAS Registry Number:85175-59-3
  • Related Blog
  • Reviews

  • Baloxavir marboxil

    Baloxavir marboxil is used to treat flu symptoms caused by influenza virus in people who have had symptoms for no more than 48 hours. Baloxavir marboxil will not treat the common cold. Baloxavir marboxil is for adults and children who are at least 12 years old and weigh at least 88 pounds (40 kilograms).

  • Everything You Need To Know About Active Pharmaceutical Ingredients (API In Pharma)

    Sandoo, as a professional API manufactruer in China, we produces a wide range of active pharmaceutical ingredients which can be used in the production of medicines in different applications. Our products are produced under strict procedures and cGMP (Current Good Manufacturing Practices). In addtion, we can also customize new pharmaceutical compounds for new drugs.

  • Differences Between Pharmaceutical Raw Materials, Excipients and Pharmaceutical Intermediates

    In the pharmaceutical industry, there are various names of raw materials, such as pharmaceutical raw materials, pharmaceutical intermediates and pharmaceutical excipients in the process of pharmaceutical production. This article will take everyone to recognize these three concepts.

  • Why API manufacturing companies almostly in China?

    In the chemical API industry, developed countries such as the United States and Europe occupy a dominant position in the field of patented APIs with high added value by virtue of their advantages in research and development, production technology, and intellectual property protection...

  • What are the raw materials required for pharmaceutical industry?

    Pharmaceutical industry has a lot of constraints and specialties which make it stand on a completely differents scale than any other industries. Being closely related to the medical field and also complementary to it, the pharmaceutical industry needs utmost care and precision in each and every aspect of the field ranging from collecting the raw materials to getting the final product ready for supply in the market.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept